Research Library

For research involving human embryos and other controversial subjects, science journals should require ethics statements from researchers detailing research oversight, what embryos were used, how many and for how long. This will help increase transparency and improve communication with the public, writes Science and Technology Policy Fellow Kirstin R.W. Matthews.

To better reflect the iterative collaboration necessary for scientific progress, the Nobel Prize must expand its recognition to the many contributors of winning discoveries as well as diversify the selection committee, thereby also expanding recognition of the work of underrepresented minorities, argues this Baker Institute Blog post.

Circular processes cannot solve the sustainability problem, but critically implementing circularity with system-level thinking can help to urgently adopt a more resilient, regenerative model for avoiding resource scarcity while fostering economic growth, argues a Forbes piece co-authored by Rachel Meidl.

Baker Institute health policy experts provide links to some of the sources they found helpful in understanding developments in the coronavirus outbreak.

While the U.S. still maintains the overall lead in Nobel prizes (with the exception of literature), the rate at which American scientists have been awarded the prize has declined since the late 1970s. Fellow Kirstin R.W. Matthews and postdoctoral fellow Kenneth M. Evans explore the state of scientific collaboration in the U.S. in this Baker Institute blog: https://bit.ly/2yiNhzF

Drug policy has experienced an interesting shift recently. Along with legalization of medical and recreational marijuana, many states are also reducing penalties for nonviolent drug offenses and placing greater focus on treatment for drug users. The emphasis on treatment and rehabilitation for drug users is the result of many factors, including recognition that the drug war has not reduced drug use, a desire to reduce the prison population and save money, and a surge in the rate of overdoses from opioid and heroin use. What remains to be seen is whether the current popularity of drug treatment will become a more permanent feature of drug policy. In this Baker Institute Viewpoints series, five experts on drug policy examine the question, “Is the current emphasis on treatment in drug policy a short-term trend or is it here to stay?”